Performance & Innovation !
|
COMPETITIVE AND BUSINESS INTELLIGENCE |
BIO-PHARMACEUTICS
|
|
|
Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
LEIDEN, The Netherlands - Top Institute Pharma announced on January 16, 2008 a highly promising research project that is aimed at the development of a malaria vaccine. This TI Pharma project will be an expansion of important findings from previous studies.
Shrimp Eyed as Nouvelle Medium for Vaccine Production
First steps will focus on validation, development of production systems
Advanced BioNutrition Corp. (Columbia, Md.) has received a $1.7 million contract to develop a shrimp-based production system for vaccines and monoclonal antibodies.
Tepha, Inc. Receives FDA Clearance for First Medical Device Derived from New Class of Biopolymers
Cambridge, MA – Tepha, Inc., a privately held medical device company, today announced that the FDA has cleared its TephaFLEX® Absorbable Suture product for marketing in the U.S.
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
KENILWORTH, New Jersey - Highlights key data at the 42nd annual meeting of the European Association for the Study of the Liver (EASL)
Schering-Plough Corporation (NYSE: SGP) reaffirms its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.
Women Taking Daily Aspirin Have Lower Death Risks Says New Study
A new American study says that women who take low to moderate doses of aspirin every day have a reduced risk of dying from any cause, but especially from heart-related illness.
New Human Cell-Produced Treatment for Anaemia Associated With Chronic Kidney Disease Now Available
BASINGSTOKE, England and COLOGNE, Germany -Today, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX:SHQ) launched DYNEPO(R) (epoetin delta) in Germany, completing the initial step of a launch programme planned for Europe over the coming months.
Pfizer axes 10,000 jobs in cost-cutting bid
With the ever-increasing threat of generic drug competition, Pfizer has reported that is to cut 10,000 jobs in an attempt to limit its annual costs.
<<< 1 2 3 4 5 6 7 >>> |
|
|
|
FREE FEEDBACK |
How often do you visit this site? |
|
WEB PARTNERS |
|
|
|
|
|
|
|
|
|
|
| |
| |
| |
| |
| |
|
